Furthermore, we found that patients with high DEPDC5 expression survived longer than those with low DEPDC5 expression across different tumor types in The Cancer Genome Atlas (TCGA) cohorts, including pheochromocytoma and paraganglioma (PCPG), colonic adenocarcinoma (COAD), lung adenocarcinoma (LUAD), bladder urothelial carcinoma (BLCA) (Fig. 1d). Here, DEPDC5 is linked to bladder transitional cell carcinoma.